ALCAM
ALCAM (CD166 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.
Overview
Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts. Promotes T-cell activation and proliferation via its interactions with CD6. Contributes to the formation and maturation of the immunological synapse via its interactions with CD6.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Fluorouracil.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ALCAM (CD166 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.
- 1 · What it is
ALCAM (CD166 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.
- 2 · What goes wrong in cancer
Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts. Promotes T-cell activation and proliferation via its interactions with CD6.
- 3 · How drugs use it
No product in this corpus aims at ALCAM yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:400 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13740 (protein name, function text, keywords and locations (REST API)); CIViC gene ALCAM (1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer (GraphQL API, CC0))
Biology
Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts. Promotes T-cell activation and proliferation via its interactions with CD6. Contributes to the formation and maturation of the immunological synapse via its interactions with CD6. Mediates homotypic interactions with cells that express ALCAM. Acts as a ligand for the LILRB4 receptor, enhancing LILRB4-mediated inhibition of T cell proliferation. Required for normal haematopoietic stem cell engraftment in the bone marrow. Location: Cell membrane; Cell projection, axon; Cell projection, dendrite; Secreted (UniProt). Locus 3q13.11 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ALCAM" OR ABSTRACT:"ALCAM" OR TITLE:"activated leukocyte cell adhesion molecule" OR ABSTRACT:"activated leukocyte cell adhesion molecule" OR TITLE:"CD166 antigen" OR ABSTRACT:"CD166 antigen" OR TITLE:"CD166" OR ABSTRACT:"CD166") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ALCAM, not a curated reading list.